Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer.

Yat Hang ToKoen DegelingSuzanne KosmiderRachel WongMargaret LeeCatherine DunnGrace GardAzim JalaliVanessa WongMaarten IJzermanPeter GibbsJeanne Tie

Published in: PharmacoEconomics (2021)

Circulating tumour-guided AC is a potentially cost-effective strategy towards reducing overtreatment in stage II colorectal cancer. Results from ongoing randomised clinical studies will be important to reduce uncertainty in the estimates.

Keyphrases

clinical trial
open label
circulating tumor
cell free
single molecule
double blind
randomized controlled trial
human health
nucleic acid